Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.60    -0.05 (-1.08%)
Bid:
4.60
Ask:
4.70
Spread: 0.10 (2.174%)
Market Cap: £220.78m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

Technical Paper Series - Intoxication launched

17 Dec 2025 07:00

RNS Number : 9169L
Seeing Machines Limited
17 December 2025
 

PRESS RELEASE

 

Seeing Machines Technical Paper Series on Non-Fatigue Impairment launched

Alcohol-related driver impairment remains a key factor in road accidents globally as current roadside strategies don't go far enough

Canberra, 17 December 2025: Seeing Machines Limited, a global leader in vision-based monitoring technology, has released Part One of its new Technical Paper series, dedicated to advancing the understanding and detection of non-fatigue driver impairment, starting with intoxication. This initiative marks a major step in the company's broader focus on leveraging its Driver Monitoring System (DMS) technology to address critical safety challenges on roads, globally.

Alcohol continues to be a leading cause of road trauma worldwide, contributing significantly to fatalities and injuries despite ongoing roadside based preventative efforts. Recognising these persistent risks, Seeing Machines has launched its capability to harness the power of DMS technology to identify impairment from alcohol in real time.

The Company's latest research highlights the limitations of relying solely on Blood Alcohol Concentration (BAC) as a benchmark for impairment. Traditional approaches often overlook the way impairment unfolds over time, resulting in gaps between BAC progression and real-world driver performance. Seeing Machines' DMS technology aims to bridge this divide by directly assessing functional impairment in real time, ensuring enhanced detection sensitivity and more effective in-cabin intervention strategies.

"Roadside alcohol testing has delivered great reductions in road injury over many years. Our goal is to complement these existing roadside programs by leading the introduction of in-vehicle approaches," said Dr Mike Lenné, Chief Safety Officer at Seeing Machines. "By incorporating the temporal dynamics of impairment, how it evolves during both the ascending and descending phases of intoxication from alcohol as well as the complex effects of other drugs such as cannabis, our technology can reflect real-time real-world risks and provide greater safety protections to road users."

To support this approach, Seeing Machines is working with leading experts and universities, conducting pioneering experiments that explore the disconnect between BAC readings and actual driver impairment. These collaborations underscore the Company's commitment to developing solutions that align technological innovation with real-world safety outcomes.

Part One of the Technical Paper series is now available, with future instalments set to explore additional aspects of non-fatigue impairment, including from cannabis, and further enhance the capabilities of DMS technology for road safety.

Click here for Part One: https://seeingmachines.com/technical-paper-series-intoxication

-ends-

About Seeing Machines (LSE: SEE)

Seeing Machines is a global company founded in 2000 and headquartered in Australia, is an industry leader in vision-based monitoring technology that enable machines to see, understand and assist people. Seeing Machines is revolutionising global transport safety. Its technology portfolio of AI algorithms, embedded processing and optics, power products that need to deliver reliable real-time understanding of vehicle operators. The technology spans the critical measurement of where a driver is looking, through to classification of their cognitive state as it applies to accident risk. Reliable "driver state" measurement is the end-goal of Driver Monitoring Systems (DMS) technology. Seeing Machines develops DMS technology to drive safety for Automotive, Commercial Fleet, Off-road and Aviation. The company has offices in Australia, USA, Europe and Asia, and supplies technology solutions and services to industry leaders in each market vertical. www.seeingmachines.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEDLBFELLZFBK
Date   Source Headline
11th Mar 20097:00 amRNSReviewed Interim Results
18th Feb 20097:00 amRNSRestructuring of the business
28th Jan 20099:41 amRNSTrading update and notice of results
1st Dec 20088:14 amRNSChange of Registered Office
27th Nov 20088:08 amRNSResult of AGM
29th Oct 200810:52 amRNSNotice of AGM
23rd Sep 20087:00 amRNSFinal Results
17th Sep 20088:37 amRNSNotice of Final Results
26th Aug 20088:33 amRNSNEW FACEAPI PRODUCT RELEASE
23rd Jul 20087:37 amRNSFirst Expected Profit Report
7th May 20088:08 amRNSNORTH AMERICAN OPERATION
7th Apr 200812:00 pmRNSChange of Broker
4th Mar 20087:59 amRNSInterim Results
4th Mar 20087:51 amRNSMajor contract gain
13th Feb 20088:27 amRNSHolding in Company
28th Dec 20079:11 amRNSAnnual Report
11th Dec 200710:54 amRNSChange of Adviser
29th Nov 200710:03 amRNSAGM Results
8th Nov 200712:38 pmRNSDirector/PDMR Shareholding
8th Nov 200712:34 pmRNSGlaucoma Device at AAO
31st Oct 20079:26 amRNSCompletion of Placing-Replace
31st Oct 20077:01 amRNSCompletion of Placing
26th Oct 20079:35 amRNSShareholder Approval
17th Oct 20072:21 pmRNSDirector/PDMR Shareholding
15th Oct 20079:23 amRNSCFO Appointment
25th Sep 200710:23 amRNSFurther Placing
24th Sep 20071:12 pmRNSFinal Results
24th Sep 20071:00 pmRNSFundraising
15th Aug 200712:43 pmRNSAIM Rule 26 Compliance
15th Aug 20079:27 amRNSFDA Approval for Truefield
2nd Jul 20077:01 amRNSNew Product Releases
29th Jun 200710:11 amRNSMaster License Agreement
22nd May 200711:15 amRNSLicensing agreement signed
8th May 20077:02 amRNSGlaucoma Device Demonstrated
28th Mar 20072:40 pmRNSInterim Results
14th Mar 200710:45 amRNSAward win for glaucoma device
12th Mar 20077:02 amRNSAddition to product released
19th Dec 200610:06 amRNSTotal Voting Rights
30th Nov 20068:27 amRNSAGM Statement
9th Nov 20067:01 amRNSGlaucoma Study Re-commences
2nd Nov 20067:01 amRNSNew Product
19th Oct 20065:38 pmRNSFinal Results - Replacement
19th Oct 200611:29 amRNSFinal Results
18th Oct 200611:04 amRNSDirectorate Change
17th Oct 20063:20 pmRNSNew Version of faceLAB
21st Sep 20064:41 pmRNSIssue of Equity
18th Sep 200611:24 amRNSAutomotive progress
18th Sep 20069:45 amRNSGlaucoma Grant Signed
30th Aug 200611:46 amRNSClinical Study Results
14th Aug 200610:57 amRNSGrant Approval

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.